Biogen Inc. (BIIB)
Largest Insider Buys in Sector
BIIB Stock Price History Chart
BIIB Stock Performance
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. …
Insider Activity of Biogen Inc.
Over the last 12 months, insiders at Biogen Inc. have bought $101,256 and sold $463,262 worth of Biogen Inc. stock.
On average, over the past 5 years, insiders at Biogen Inc. have bought $612,372 and sold $2.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rowinsky Eric K (director) — $303,767.
The last purchase of 455 shares for transaction amount of $101,256 was made by Rowinsky Eric K (director) on 2024‑02‑15.
List of Insider Buy and Sell Transactions, Biogen Inc.
| 2024-12-09 | Sale | Head of Development | 110 <0.0001% | $157.21 | $17,293 | -3.72% | ||
| 2024-09-03 | Sale | Head of Development | 431 0.0003% | $204.22 | $88,019 | -11.28% | ||
| 2024-04-02 | Sale | Head of Development | 93 <0.0001% | $213.09 | $19,817 | -2.76% | ||
| 2024-02-22 | Sale | Head of Development | 262 0.0002% | $221.23 | $57,962 | -7.88% | ||
| 2024-02-16 | Sale | Head of Development | 108 <0.0001% | $221.49 | $23,921 | -6.44% | ||
| 2024-02-15 | director | 455 0.0003% | $222.54 | $101,256 | -8.22% | |||
| 2024-02-12 | Sale | Head of Development | 419 0.0003% | $239.45 | $100,330 | -16.08% | ||
| 2024-02-02 | Sale | Head of Development | 634 0.0004% | $245.93 | $155,920 | -15.43% | ||
| 2023-12-11 | Sale | Head of Development | 110 <0.0001% | $248.00 | $27,280 | -11.66% | ||
| 2023-09-05 | Sale | Head of Development | 431 0.0003% | $269.43 | $116,124 | -14.17% | ||
| 2023-07-03 | Sale | Head of Development | 81 <0.0001% | $282.87 | $22,912 | -15.41% | ||
| 2023-04-28 | Sale | EVP, Human Resources | 2,681 0.0018% | $300.00 | $804,300 | -15.82% | ||
| 2023-04-04 | Sale | Head of Development | 91 <0.0001% | $277.11 | $25,217 | -5.93% | ||
| 2023-03-28 | Sale | Head of Development | 568 0.0004% | $270.06 | $153,394 | -3.55% | ||
| 2022-11-14 | Sale | EVP, Human Resources | 5,610 0.0039% | $300.11 | $1.68M | -7.17% | ||
| 2022-10-27 | Sale | EVP Chief Legal Off & Corp Sec | 5,532 0.0039% | $280.70 | $1.55M | +0.81% | ||
| 2021-06-07 | Sale | Head of Research & Development | 7,672 0.0057% | $440.00 | $3.38M | -39.39% | ||
| 2021-06-07 | Sale | Head of Glob Prod Strat & Com | 3,087 0.0023% | $440.00 | $1.36M | -39.39% | ||
| 2021-06-04 | Sale | director | 360 0.0002% | $274.17 | $98,701 | -15.86% | ||
| 2021-02-09 | director | 898 0.0006% | $267.00 | $239,766 | +1.75% |
Insider Historical Profitability
| Rowinsky Eric K | director | 20629 0.0142% | $146.47 | 1 | 6 | |
| DENNER ALEXANDER J | director | 643000 0.4413% | $146.47 | 12 | 4 | +0.39% |
| Vounatsos Michel | Chief Executive Officer | 34810 0.0239% | $146.47 | 5 | 0 | +8.6% |
| DORSA CAROLINE | director | 17093 0.0117% | $146.47 | 8 | 2 | +28.27% |
| PAPADOPOULOS STELIOS | director | 5000 0.0034% | $146.47 | 1 | 2 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $3.57B | 11.38 | 16.57M | +15.01% | +$466.42M | 0.07 | |
| PRIMECAP Management Co | $3.5B | 11.14 | 16.22M | -0.27% | -$9.44M | 2.57 | |
| BlackRock | $3.05B | 9.72 | 14.14M | -0.71% | -$21.92M | 0.07 | |
| State Street | $1.45B | 4.63 | 6.75M | -2.86% | -$42.84M | 0.06 | |
| T Rowe Price Investment Management Inc | $1.11B | 3.55 | 5.17M | -3.5% | -$40.4M | 0.68 |